Franklin Lakes, NJ – BD (Becton, Dickinson, and Company), a prominent global medical technology company, has secured 510(k) clearances from the U.S. Federal Drug Administration (FDA) for its innovative blood collection device, the BD MiniDraw™ Capillary Blood Collection System. This novel system obtains blood samples from a fingerstick, delivering lab-quality results for commonly ordered blood tests.
The BD MiniDraw™ System presents a less invasive alternative to traditional venous blood draws, utilizing capillary blood collected from a patient’s finger by a trained healthcare worker. Also, This eliminates the need for a phlebotomist to draw blood from a vein, providing a more convenient and accessible option for patients. The system’s design allows lab-quality blood test results from a fraction of the volume required in traditional venous collections.
Moreover, The 510(k) clearances encompass low-volume blood collection for a lipid panel, selected chemistry tests, and hemoglobin and hematocrit (H&H) testing. These tests, are vital for diagnosing and monitoring various chronic conditions, including hypertension and high cholesterol. BD anticipates expanding the range of blood tests facilitated by the BD MiniDraw™ Collection System....READ MORE
BD and Edwards Lifesciences’ announced a definitive agreement under which BD will acquire Edwards’ Critical Care product group (“Critical Care”), a global leader in advan...
Franklin Lakes, NJ – BD (Becton, Dickinson, and Company), a prominent global medical technology company, has secured 510(k) clearances from the U.S. Federal Drug Administ...
A virtual marketplace leading your business into the future
